ACCESS Newswire

Northway Biotech

16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release

Share
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
tiakis Biotech AG and Northway Biotech collaboration
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat

"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.

The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.

Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."

André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."

By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.

About Tiprelestat

tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.

About tiakis Biotech AG

tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).

About Northway Biotech

Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.

Contact Information

Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com

SOURCE: Northway Biotech

To view this piece of content from stats.newswire.com, please give your consent at the top of this page.

View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Fermi Announces Third Quarter 2026 Earnings Release and Call Date12.10.2026 22:01:00 CEST | Press release

DALLAS, TX / ACCESS Newswire / October 12, 2026 / Fermi Inc. (NASDAQ:FRMI)(LSE:FRMI), operating as Fermi America™ ("Fermi" or the "Company"), today announced that it plans to release third quarter 2026 financial results at 7 a.m. Eastern Time / 12 p.m. British Time on Thursday, November 12, 2026. This announcement will be followed by an earnings conference call at 9 a.m. Eastern Time / 2 p.m. British Time. The Company's earnings release and supplemental information will be posted to the Investors section of the Company's website prior to the conference call. To join the live conference call, dial 888-506-0062 in the U.S. or +1 973-528-0011 internationally approximately 15 minutes prior to the scheduled start time and refer to conference code 176575. The call will also be webcast in a listen-only mode and can be accessed through the Investor Relations Events & Presentations page of Fermi's website. A replay of the webcast will be available for a period of one year. Investor Contact Barr

Chervon Names Charlie Harte Director of Field Sales & Recruiting - Canada12.10.2026 16:00:00 CEST | Press release

NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Charlie Harte joins Chervon as Director of Field Sales and Recruiting - Canada, effective Monday, October 12, 2026, reporting to Neil Harrison, VP/MD Sales and Marketing - Canada. Harte brings 15+ years of experience in the Canadian power tools, outdoor power equipment, and hand tool market. Additionally, he has 6+ years of experience selling into the commercial plumbing arena. Early in his career, Harte spent six years at Black and Decker growing into the National Sales and Marketing Manager position for B&D Canada. He subsequently became Director of Sales for Irwin Industrial Tools and then became a Director of Sales for Milwaukee Canada. Harte moved into the VP Sales position for Uponor Advanced Plumbing Solutions. Harte has an impressive track record in field sales leadership and strategic account development. He is known for his ability to build and manage high-performance sales teams throughout Canada. "Charlie brings an outst

Chervon Names Thomas G. Kentouris Vice President of Field Sales12.10.2026 15:00:00 CEST | Press release

NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Thomas G. Kentouris joins Chervon as Vice President of Field Sales, effective Monday, October 12, 2026, reporting to Matt DeFeo, SVP of Sales Training and Recruiting. Kentouris brings 14+ years of Power Tool and Outdoor Power Equipment experience at TTI. His career began as a sales rep and advanced through a series of increasingly responsible positions, culminating in SVP of Field Sales for Eastern U.S.A. Kentouris delivered exceptional sales growth results year after year in his areas of responsibility. His ability to develop store-level partnerships and store-level sell-through programs all resulted in exceptional levels of success. Kentouris distinguished himself as an outstanding recruiting talent as he and his teams were responsible for recruiting over 2,000 high potential recent college graduates into the TTI system. Kentouris did an amazing job mentoring, developing, and promoting hundreds of his people into higher level posi

Chervon Names Randall Durkan Vice President of Supply Chain - North America12.10.2026 15:00:00 CEST | Press release

NAPERVILLE, IL / ACCESS Newswire / October 12, 2026 / Randy Durkan joins Chervon as Vice President of Supply Chain - North America, effective Monday, October 12, 2026, reporting to CEO Joe Galli. Randy Durkan brings over 25 years of supply chain management experience, including extensive leadership in power tools, hand tools, and outdoor power equipment. He has proven experience building high-performance supply chain teams and has consistently delivered outstanding service levels, inventory optimization, and cost-reduction results. Durkan is known for developing strong supply chain partnerships with key customers, driving cross-functional collaboration, and deploying technology to achieve world-class supply chain performance. He began his early supply chain career in Bentonville, Arkansas, supporting Walmart-focused collaboration across several consumer goods companies. His work at Vi-Jon contributed to Walmart's 2008 Supplier of the Year Award. Durkan then spent six years in supply ch

Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 20269.10.2026 17:00:00 CEST | Press release

MIAMI, FL / ACCESS Newswire / October 9, 2026 / Miami Fashion Week® (MIAFW) celebrates its 10th anniversary this year, returning October 13-18, 2026 featuring industry programming, runway shows, and special events bringing together international designers, Latin American talent and Miami's creative community. For a decade, MIAFW has served as a bridge between Miami and the international fashion industry, creating a platform for designers while expanding beyond the runway through sustainability, technology, education and cultural exchange. The milestone edition brings together international designers, Latin American talent, fashion innovation and a new Stitch Lab retail experience Throughout these ten years, MIAFW has pioneered initiatives at the intersection of fashion, sustainability and technology. Founded in 2017, the MIAFW Summit created a space for dialogue and education around the industry's evolving challenges and opportunities. Building on that vision, the Virtual Fashion Award

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye